Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06448247 · ClinicalTrials.gov registry record · Phase 1
A Study of SPY001-001 in Healthy Volunteers
A Phase 1 study, sponsored by Spyre Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 96
- Enrollment target
NCT06448247: Completed Phase 1 study, sponsored by Spyre Therapeutics.
NCT06448247 is a Phase 1 study that has completed, run by Spyre Therapeutics. The registered enrollment target is 96 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06448247, a Phase 1 study, has completed, sponsored by Spyre Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 96 participants
- Enrollment target
Study Summary
This is a Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose, first in human safety, tolerability, and pharmacokinetic study of SPY001-001 in healthy participants.
Primary Outcome
Incidence, severity, and causal relationship of TEAEs
Interventions
- OTHER Placebo
- DRUG SPY001-001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2024-06-06 |
| Est. Completion | 2026-03-10 |
| Phase | Phase 1 |
What the finished NCT06448247 record still lists
NCT06448247 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 96 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06448247 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06448247 about?
NCT06448247 is a clinical study titled "A Study of SPY001-001 in Healthy Volunteers". This is a Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose, first in human safety, tolerability, and pharmacokinetic study of SPY001-001 in healthy participants.
What is the current status of trial NCT06448247?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 96 participants. The study started on 2024-06-06. Estimated completion is 2026-03-10.
What interventions are being tested in trial NCT06448247?
The interventions under investigation include: Placebo (OTHER), SPY001-001 (DRUG).
Who is sponsoring clinical trial NCT06448247?
This trial is sponsored by Spyre Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06448247's enrollment target sits among peer trials
96 600th of 2000 higher than 1,391 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03401762 · 96 participants · NA
Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke
- NCT03471260 · 96 participants · Phase 1
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- NCT03549559 · 96 participants · NA
Imaging Histone Deacetylase in the Heart
- NCT03841058 · 96 participants · Phase 2
Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI